MODIFIED RELEASE FORMULATIONS OF PRIDOPIDINE

摘要

The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or as pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release said oral dosage form.